315 related articles for article (PubMed ID: 32421446)
21. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
22. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
23. Targeted agents: management of dermatologic toxicities.
Burtness B
J Natl Compr Canc Netw; 2014 May; 12(5 Suppl):793-6. PubMed ID: 24853219
[TBL] [Abstract][Full Text] [Related]
24. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
Wu PA; Balagula Y; Lacouture ME; Anadkat MJ
Curr Opin Oncol; 2011 Jul; 23(4):343-51. PubMed ID: 21537180
[TBL] [Abstract][Full Text] [Related]
25. [Radiotherapy and New Cancer Drugs - New Side Effects ?].
Nakamura S
Gan To Kagaku Ryoho; 2018 Mar; 45(3):424-427. PubMed ID: 29650897
[TBL] [Abstract][Full Text] [Related]
26. Cardiac toxicities of anticancer treatments: chemotherapy, targeted therapy and immunotherapy.
Zarifa A; Albittar A; Kim PY; Hassan S; Palaskas N; Iliescu C; Durand JB; Lopez-Mattei J
Curr Opin Cardiol; 2019 Jul; 34(4):441-450. PubMed ID: 31082852
[TBL] [Abstract][Full Text] [Related]
27. Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors.
Peng Y; Li Q; Zhang J; Shen W; Zhang X; Sun C; Cui H
Biosci Trends; 2019 Jan; 12(6):537-552. PubMed ID: 30555112
[TBL] [Abstract][Full Text] [Related]
28. Unintended Consequences of Systemic and Ablative Oncologic Therapy in the Abdomen and Pelvis.
Birch JC; Khatri G; Watumull LM; Arriaga YE; Leyendecker JR
Radiographics; 2018; 38(4):1158-1179. PubMed ID: 29995613
[TBL] [Abstract][Full Text] [Related]
29. Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy.
Rzepecki AK; Cheng H; McLellan BN
J Am Acad Dermatol; 2018 Sep; 79(3):545-555. PubMed ID: 29733938
[TBL] [Abstract][Full Text] [Related]
30. Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer.
Tang N; Ratner D
Dermatol Surg; 2016 Jan; 42 Suppl 1():S40-8. PubMed ID: 26730973
[TBL] [Abstract][Full Text] [Related]
31. Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies.
Ransohoff JD; Kwong BY
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):834-851. PubMed ID: 28918995
[TBL] [Abstract][Full Text] [Related]
32. Cutaneous Complications of Targeted Melanoma Therapy.
de Golian E; Kwong BY; Swetter SM; Pugliese SB
Curr Treat Options Oncol; 2016 Nov; 17(11):57. PubMed ID: 27645330
[TBL] [Abstract][Full Text] [Related]
33. Cutaneous reactions to pediatric cancer treatment part II: Targeted therapy.
Carlberg VM; Davies OMT; Brandling-Bennett HA; Leary SES; Huang JT; Coughlin CC; Gupta D
Pediatr Dermatol; 2021 Jan; 38(1):18-30. PubMed ID: 33378085
[TBL] [Abstract][Full Text] [Related]
34. Drug-related problems with targeted/immunotherapies at an oncology outpatient clinic.
Kucuk E; Bayraktar-Ekincioglu A; Erman M; Kilickap S
J Oncol Pharm Pract; 2020 Apr; 26(3):595-602. PubMed ID: 31342849
[TBL] [Abstract][Full Text] [Related]
35. Pathogenesis of Oral Toxicities Associated with Targeted Therapy and Immunotherapy.
Villa A; Kuten-Shorrer M
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175898
[TBL] [Abstract][Full Text] [Related]
36. Adverse Events in Cancer Immunotherapy.
Abdel-Wahab N; Alshawa A; Suarez-Almazor ME
Adv Exp Med Biol; 2017; 995():155-174. PubMed ID: 28321817
[TBL] [Abstract][Full Text] [Related]
37. Dermatologic adverse events to chemotherapeutic agents, part 1: cytotoxics, epidermal growth factor receptors, multikinase inhibitors, and proteasome inhibitors.
Kyllo RL; Anadkat MJ
Semin Cutan Med Surg; 2014 Mar; 33(1):28-39. PubMed ID: 25037256
[TBL] [Abstract][Full Text] [Related]
38. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic.
Rosen AC; Case EC; Dusza SW; Balagula Y; Gordon J; West DP; Lacouture ME
Am J Clin Dermatol; 2013 Aug; 14(4):327-33. PubMed ID: 23625802
[TBL] [Abstract][Full Text] [Related]
39. Making the Grade: The Impact of Low-Grade Toxicities on Patient Preference for Treatment With Novel Agents.
Castellanos EH; Chen SC; Drexler H; Horn L
J Natl Compr Canc Netw; 2015 Dec; 13(12):1490-5. PubMed ID: 26656518
[TBL] [Abstract][Full Text] [Related]
40. Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications.
Zur E
Int J Pharm Compd; 2018; 22(6):446-454. PubMed ID: 30384344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
